• Tryp just filed an IND with the FDA for its TRP-8802 clinical candidate for its Phase 2a clinical trial
• The trial is set to commence in 2022, subject to a favorable review by the FDA
• The study will be conducted in collaboration with the University of Michigan and will aim at evaluating the safety and clinical utility of psilocybin for fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced its submission of an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (“FDA”) for its TRP-88802 clinical candidate. This application follows the commencement of Tryp’s Phase 2a clinical trial that explores psilocybin-assisted therapy’s safety and preliminary effectiveness among individuals dealing with fibromyalgia.

While making the announcement, Greg McKee, the Chairman and Chief Executive Officer of Tryp, noted, “We have been working diligently to complete this IND submission and are eager to initiate what will be one of the first evaluations of psilocybin to treat fibromyalgia in a Phase 2 study,” (https://ibn.fm/KVqCt).

This trial is being conducted in collaboration with the University of Michigan, spearheaded by Kevin Boehnke, Ph.D. from the university. It will involve 20 fibromyalgia patients and include various exploratory endpoints, particularly given the high prevalence of co-morbidities that include, but are not limited to anxiety, depression, and poor sleep quality.

Since its inception, Tryp has aimed to lead the next wave of psychedelic drug development, pushing beyond mental health. Its focus on psilocybin-based treatments for chronic pain and other indications has proven useful and highly effective. With this specific study, the company seeks to offer a more effective fibromyalgia solution than those that are currently available in the market today. It also aims to provide a long lasting solution with fewer side effects, ultimately affording patients better treatment for their condition.

“Many fibromyalgia patients find insufficient relief from the currently available, FDA-approved treatments for the disease due to their limited efficacy and significant side effects. We have an opportunity with Tryp to conduct a Phase 2a study that evaluates the safety and clinical utility of psilocybin for fibromyalgia as we target the origins of the disease rather than simply treating patient symptoms,” noted Dr. Boehnke.

Research has shown that the administration of psilocybin increases neuroplasticity while also addressing disrupted neural connections that are typically associated with fibromyalgia and other nociplastic pain indications. This Phase 2a study will seek to capitalize on that, starting with the administration of TRP-8802, coupled with psychotherapy. The study is expected to commence in 2022, subject to a favorable review of the IND by the FDA.

“Through our close collaboration with Dr. Boehnke and other experts in the space, we have an appreciation of the limitations of current treatments for this disease and a determination to develop a more effective therapy for the millions of patients suffering from fibromyalgia,” noted Mr. McKee.

For more information, visit the company’s website at www.TrypTherapeutics.com. 

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.